These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23010697)

  • 1. Safety of CETP inhibition.
    Duivenvoorden R; Fayad ZA
    Curr Opin Lipidol; 2012 Dec; 23(6):518-24. PubMed ID: 23010697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
    Shinkai H
    Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
    Mohammadpour AH; Akhlaghi F
    Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H
    Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
    Niesor EJ
    Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dalcetrapib: a review of Phase II data.
    Robinson JG
    Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.
    Rhainds D; Arsenault BJ; Brodeur MR; Tardif JC
    Future Cardiol; 2012 Jul; 8(4):513-31. PubMed ID: 22871191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for cholesteryl ester transfer protein inhibition.
    Hewing B; Fisher EA
    Curr Opin Lipidol; 2012 Aug; 23(4):372-6. PubMed ID: 22517614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future of cholesteryl ester transfer protein inhibitors.
    Rader DJ; deGoma EM
    Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
    Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
    Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
    Barter P; Rye KA
    Trends Pharmacol Sci; 2011 Dec; 32(12):694-9. PubMed ID: 22088767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
    Masson D
    Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.
    Kalgutkar AS; Frederick KS; Hatch HL; Ambler CM; Perry DA; Garigipati RS; Chang GC; Lefker BA; Clark RW; Morehouse LA; Francone O; Hu X
    Xenobiotica; 2014 Jul; 44(7):591-605. PubMed ID: 24380613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.
    Goldberg AS; Hegele RA
    Drug Des Devel Ther; 2012; 6():251-9. PubMed ID: 23055695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors.
    Miyares MA
    Ann Pharmacother; 2011 Jan; 45(1):84-94. PubMed ID: 21205945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes.
    Rios FJ; Neves KB; Nguyen Dinh Cat A; Even S; Palacios R; Montezano AC; Touyz RM
    J Pharmacol Exp Ther; 2015 Apr; 353(1):27-34. PubMed ID: 25617244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDL metabolism and CETP inhibition.
    Barkowski RS; Frishman WH
    Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical characterization of cholesteryl ester transfer protein inhibitors.
    Ranalletta M; Bierilo KK; Chen Y; Milot D; Chen Q; Tung E; Houde C; Elowe NH; Garcia-Calvo M; Porter G; Eveland S; Frantz-Wattley B; Kavana M; Addona G; Sinclair P; Sparrow C; O'Neill EA; Koblan KS; Sitlani A; Hubbard B; Fisher TS
    J Lipid Res; 2010 Sep; 51(9):2739-52. PubMed ID: 20458119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R; Joy TR
    Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.